1. Home
  2. AACG vs NXTC Comparison

AACG vs NXTC Comparison

Compare AACG & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AACG

ATA Creativity Global

HOLD

Current Price

$1.20

Market Cap

32.7M

Sector

Real Estate

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

N/A

Current Price

$9.74

Market Cap

39.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AACG
NXTC
Founded
1999
2015
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
32.7M
39.1M
IPO Year
2008
2019

Fundamental Metrics

Financial Performance
Metric
AACG
NXTC
Price
$1.20
$9.74
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
15.6K
45.6K
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$22,378,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.42
52 Week High
$2.58
$15.74

Technical Indicators

Market Signals
Indicator
AACG
NXTC
Relative Strength Index (RSI) 56.32 45.35
Support Level $1.08 $8.45
Resistance Level $1.36 $10.81
Average True Range (ATR) 0.10 0.74
MACD -0.00 0.05
Stochastic Oscillator 53.27 45.80

Price Performance

Historical Comparison
AACG
NXTC

About AACG ATA Creativity Global

ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: